| AMGN:Amgen Inc | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
0.90% $2.56
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS |
|
| PR Newswire |
|
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Robert A. Bradway, chairman and chief executive officer. |
| Full Story → |
|
| Headline News |
|
| AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS |
| 4:01p ET April 28 '25 PR Newswire |
|
|
| AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO |
| 12:48p ET April 25 '25 PR Newswire |
|
|
| IMDELLTRA(R) DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER |
| 9:01a ET April 11 '25 PR Newswire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| May 2 '25. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, May 1 '25. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
0.14%
